Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

United Therapeutics Replaces Oral Treprostinil With Lilly’s Tadalafil In PAH – For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

Non-shocking Phase III blowup coincides with U.S. deal for rights to drug already cleared for erectile dysfunction.

You may also be interested in...



Despite Latest Oral Remodulin Phase III Flop, UTHR Says It Still Has Enough Data For FDA

The company tells skeptical analysts it will pursue a limited monotherapy label based on a single positive Phase III study in the wake of a second combination trial failure.

Despite Latest Oral Remodulin Phase III Flop, UTHR Says It Still Has Enough Data For FDA

The company tells skeptical analysts it will pursue a limited monotherapy label based on a single positive Phase III study in the wake of a second combination trial failure.

PAH’s Two Main Players Edging Toward Head-To-Head Competition

Although Pfizer Inc. and Gilead Sciences can be found at its margins, the pulmonary arterial hypertension space largely is a two-company competition. Currently, the two main players – United Therapeutics Corp. and Switzerland's Actelion Ltd. – have staked out a competitive advantage in a different portion of the space, but they are about to compete directly.

Related Content

Topics

UsernamePublicRestriction

Register

PS067027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel